Pharmaceutical Executive Daily: FDA Issues CRL to Elevar Therapeutics

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today's Pharmaceutical Executive Daily, a new industry analysis warns that direct-to-patient pharma platforms are scaling faster than the safety infrastructure needed to support them, FDA issues a complete response letter to Elevar Therapeutics over manufacturing deficiencies in its liver cancer combination therapy, and Insilico Medicine deepens its partnership with China Medical System Holdings in a new AI-powered drug discovery collaboration worth up to $177 million.

Direct-to-patient (DTP), pharma platforms are scaling rapidly, but a new analysis finds the clinical safety infrastructure behind them has not kept pace. Prescriptions filled through many DTP platforms don't flow back into a patient's electronic health record, creating blind spots for physicians managing drug interactions and care coordination. The report identifies metabolic, mental health, and other stigma-sensitive categories as the areas of fastest growth and greatest risk. Industry watchers say the fix isn't complicated in concept, closer integration with primary care records, but will require platforms to prioritize it as a product decision rather than wait for regulation.

FDA has issued a complete response letter to Elevar Therapeutics for its combination of rivoceranib and camrelizumab, a proposed first-line treatment for unresectable or metastatic hepatocellular carcinoma. The rejection was tied to manufacturing deficiencies identified during a facility inspection, not to concerns about clinical efficacy or safety. The combination was supported by Phase III trial data showing a median overall survival of 23.8 months. The letter marks the latest development following FDA's recent decision to pause the release of new CRLs pending a response to a citizen's petition.

Finally, Insilico Medicine has entered it’s second collaboration with China Medical System Holdings in three months, this time targeting a central nervous system indication using a novel mechanism identified through Insilico's PandaOmics platform. The deal has the potiential to bring Insilico up to $177 million in milestone payments plus royalties and is part of a broader pattern for Insilico, which has struck several major AI-drug-discovery partnerships in 2026, including deals with Eli Lilly and SK Biopharmaceuticals.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.